Welcome to IJPT

This comprehensive exploration delves into the multifaceted relationship between Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and cancer, with a specific focus on colorectal cancer. The synthesis of extensive clinical data establishes NSAIDs as pivotal in cancer treatment, particularly in colorectal cancer prevention. The National Comprehensive Cancer Network's recognition of NSAIDs in the 2017 colorectal cancer guide signifies a milestone in integrating these drugs into clinical protocols. While long-term NSAID use exhibits anticancer effects, the associated side effects necessitate a nuanced consideration of risks and benefits for individual patients contemplating cancer chemoprophylaxis. The review encompasses the mechanisms underlying NSAID action, their impact on inflammatory pathways, angiogenesis, immune modulation, and their role in preventing cancer metastasis. The nuanced discussion highlights the need for future research, emphasizing molecular classifications, population-specific studies, and optimal NSAID dosage for maximizing anticancer benefits.

The lungs play a crucial role in sustaining life by collaborating with the heart and circulatory system to supply essential oxygen to the body. They possess a remarkable reserve capacity, working efficiently even under various conditions. Similarly, the heart and circulatory system have a reserve capacity, enabling cancerous lung tumours to grow over several years without hindering lung function. Additionally, the lungs have fewer nerves for pain transmission, allowing cancer to progress for an extended period without causing noticeable symptoms. Despite being a global health concern, lung cancer is often asymptomatic in its early stages, making it a challenging disease to detect. The prognosis for lung cancer, particularly non-small cell lung cancer (NSCLC), is generally more favourable when diagnosed early. NSCLC is considered a lifethreatening condition, and early detection coupled with prompt intervention is crucial. Treatment options such as surgery, radiation therapy, and chemotherapy can significantly contribute to a positive prognosis for individuals with non-small cell lung cancer. Early diagnosis and swift initiation of appropriate therapies are paramount in improving outcomes and increasing the chances of successful treatment

Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. In present study transdermal drug delivery of Haloperidol was developed to overcome the first pass metabolism and to reduce frequency of dosing compared to oral route. Matrix type of transdermal patches was developed by using polymers various Xanthan gum, MethocelK15M and MethocelK100M as polymers Transdermal patches were prepared by employing solvent casting method. Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation, Thickness, Folding endurance, Drug content, Moisture uptake, Moisture content and all the results were found to be were found to be with in the pharmacopeial limits, invitro drug release studies by using dialysis membrane. Among all the 9 formulations F7 formulation which containMethocel K100M 100 mg had shown 97.83% cumulative drug release within 12 hours

Darolutamide-loaded nanospheres were developed and characterized for enhancing its therapeutic efficacy in this study. Due to its poor aqueous solubility and bioavailability, darolutamide is a potent anti-androgen used in the treatment of prostate cancer. Nanotechnology-based approaches, such as nanospheres, may provide solutions to these problems. As part of the formulation process, darolutamide was encapsulated within nanospheres, which ensured that the release kinetics of the drug would be controlled and the stability would be improved. As a result of various characterization techniques, including dynamic light scattering (DLS) and scanning electron microscopy (SEM), spherical nanoparticles were determined to have a diameter of approximately, which are suitable for enhanced permeation and retention (EPR) in tumor tissues. According to in vitro release studies, the drug was released over an extended period of time, indicating the possibility of reducing the frequency of dosing and improving compliance among patients. Furthermore, darolutamideloaded nanospheres inhibited cell proliferation to a greater extent than free drug formulations when tested against prostate cancer cell lines. Consequently, darolutamide-loaded nanospheres may offer a promising approach to improving prostate cancer treatment outcomes. As a conclusion, our study demonstrates that darolutamide-loaded nanospheres have been successfully formulated and characterized, and that they have the potential to serve as an effective and targeted delivery mechanism for the treatment of prostate cancer

Clinical Data Management (CDM) plays a pivotal role in ensuring the integrity and regulatory compliance of vaccine trials within the pharmaceutical industry. This abstract presents findings from a survey conducted among 46 participants across 16 organizations in the Indian pharmaceutical sector, focusing on the needs and challenges of CDM specific to vaccine trials. The survey highlights widespread consensus among respondents regarding the complexity and resource limitations faced by in-house CDM units, with a majority advocating for streamlined guidelines to improve data quality and adherence to Indian Good Clinical Practice (GCP) standards. Key concerns identified include procedural heterogeneity across organizations, variability in software usage, and the perceived impact on regulatory compliance. The results underscore the industry's call for structured, systematic approaches to CDM that can support standardized data practices and facilitate regulatory adherence in vaccine development. Addressing these challenges is critical for enhancing the efficiency and reliability of vaccine trials in India's pharmaceutical landscape